{
    "clinical_study": {
        "@rank": "26662", 
        "acronym": "SERUM", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who are mAb ADA positive"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Subjects who are mAb ADA negative"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects who are mAb ADA positive"
            }, 
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects who are mAb ADA negative"
            }
        ], 
        "brief_summary": {
            "textblock": "The first 12 weeks of this study will compare the efficacy of etanercept 50 mg once-weekly\n      to placebo in subjects with rheumatoid arthritis who have not responded well to infliximab\n      or adalimumab plus methotrexate.  This comparison will be performed for all subjects and\n      separately for subjects who are anti-drug antibody positive for one of these medications.\n      From week 12 to week 24, all subjects will receive etanercept 50 mg once-weekly.  The effect\n      of anti-drug antibody status on  the efficacy of etanercept as well as the safety profile of\n      etanercept in these subjects will also be evaluated throughout the study."
        }, 
        "brief_title": "Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Met the 1987 ACR Revised Criteria for RA\n\n          2. A history of inadequate response to infliximab or adalimumab in combination with\n             methotrexate.\n\n          3. A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.\n\n        Exclusion Criteria:\n\n          1. ACR functional class IV\n\n          2. Prior treatment with etanercept; both infliximab and adalimumab; or any\n             immunosuppressive biologic agent other than infliximab or adalimumab.\n\n          3. Discontinuation of infliximab or adalimumab for a primary reason other than\n             inadequate efficacy response."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783015", 
            "org_study_id": "B1801355"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "description": "Etanercept 50 mg once-weekly", 
                "intervention_name": "Etanercept", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group B", 
                "description": "Etanercept 50 mg once-weekly", 
                "intervention_name": "Etnaercept", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group C", 
                "description": "Etanercept placebo once-weekly", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group D", 
                "description": "Etanercept placebo once-weekly", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Infliximab", 
                "TNFR-Fc fusion protein", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rheumatoid arthritis", 
            "etanercept", 
            "methotrexate", 
            "infliximab", 
            "adalimumab", 
            "anti-drug antibody"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1801355&StudyName=Study%20of%20Etanercept%20in%20Subjects%20with%20Rheumatoid%20Arthritis%20Who%20Have%20Had%20an%20Inadequate%20Response%20to%20Adalimumab%20or%20Infliximab%20Plus%20Methotrex"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Morwell", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3840"
                    }, 
                    "name": "Private Rooms of Dr Anthony Boers"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Victoria Park", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6100"
                    }, 
                    "name": "RK Will Pty Ltd"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Cliniques Universitaires Saint-Luc / Service de Rhumatologie"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yvoir", 
                        "country": "Belgium", 
                        "zip": "5530"
                    }, 
                    "name": "Cliniques Universitares-Mont Godinne"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34000"
                    }, 
                    "name": "CHU Lapeyronie"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tseung Kwan O", 
                        "country": "Hong Kong", 
                        "state": "New Territories"
                    }, 
                    "name": "Tseung Kwan O Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Queen Mary Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tuen Mun, NT", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Tuen Mun Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yuen Long, NT", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Pok Oi Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "31048"
                    }, 
                    "name": "Bnai Zion Medical Ctr"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kfar Saba", 
                        "country": "Israel", 
                        "zip": "44281"
                    }, 
                    "name": "Meir Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "Department of Rheumatology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "state": "Noord Holland", 
                        "zip": "1056 AB"
                    }, 
                    "name": "Reade (Jan Van Breemen Instituut (JBI))"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kazan", 
                        "country": "Russian Federation", 
                        "state": "Tatarstan, Respublika", 
                        "zip": "420097"
                    }, 
                    "name": "LLC Research Medical Complex Your Health"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izhevsk", 
                        "country": "Russian Federation", 
                        "zip": "426064"
                    }, 
                    "name": "LLC \"Alliance Biomedical-Russian Group\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krasnoyarsk", 
                        "country": "Russian Federation", 
                        "zip": "660022"
                    }, 
                    "name": "GOU VPO Krasnoyarsk State Med Univ"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "127473"
                    }, 
                    "name": "GOU VPO Moscow SU of Medicine & Dentistry ba"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115522"
                    }, 
                    "name": "Scientific Institute of Rheumatology of Russian Academy of Medical Science"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "129301"
                    }, 
                    "name": "City Clinical Hospital #40"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novosibirsk", 
                        "country": "Russian Federation", 
                        "zip": "630117"
                    }, 
                    "name": "FSBI Scientific and Research Institution of"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bilbao", 
                        "country": "Spain", 
                        "state": "Vizcaya", 
                        "zip": "48013"
                    }, 
                    "name": "Hospital de Basurto"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "A Coru\u00f1a", 
                        "country": "Spain", 
                        "zip": "15006"
                    }, 
                    "name": "Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a, Hospital Universitario A Coru\u00f1a"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08025"
                    }, 
                    "name": "Hospital de la Santa Creu i San Pau"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitari Vall d'Hebron"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "Hospital General Universitario Gregorio Maranon"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28007"
                    }, 
                    "name": "H.G.U. G. Mara\u00f1\u00f3n"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28046"
                    }, 
                    "name": "Hospital Universitario La Paz"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00e1laga", 
                        "country": "Spain", 
                        "zip": "29009"
                    }, 
                    "name": "Hospital Regional Universitario Carlos Haya. Hospital Civil."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41009"
                    }, 
                    "name": "H.U.V. Macarena"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41010"
                    }, 
                    "name": "Hospital Infanta Luisa"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "France", 
                "Hong Kong", 
                "Israel", 
                "Netherlands", 
                "Russian Federation", 
                "Spain"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the c-reactive protein (CRP) and Subject's General Health VAS assessment(participant rated health assessment with scores ranging 0 to 100; higher scores indicate worse health status).", 
            "measure": "Change from Baseline in Disease Activity Score Based on 28-joints Count (DAS28)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783015"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the c-reactive protein (CRP) and ubject General Health as measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = very well and 100 mm = extremely bad", 
                "measure": "Change from Baseline in Disease Activity Score Based on 28-joints Count (DAS28)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "DAS28 <3.2 = low disease activity", 
                "measure": "Number of Participants with DAS28 <3.2", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "DAS28 <2.6 = remission", 
                "measure": "Number of Participants with DAS28 <2.6", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "ACR20 response: greater than or equal to (\u2265) 20 percent (%) improvement in tender joint count; \u2265 20% improvement in swollen joint count; and \u2265 20% improvement in at least 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)", 
                "measure": "Number of Participants Acheiving American College of Rheumatology 20% (ACR20) Response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "ACR50 response: greater than or equal to (\u2265) 50 percent (%) improvement in tender or swollen joint counts and \u2265 50% improvement in 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)", 
                "measure": "Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "ACR70 response: greater than or equal to (\u2265) 70 percent (%) improvement in tender or swollen joint counts and \u2265 70% improvement in 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)", 
                "measure": "Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "ACR90 response: greater than or equal to (\u2265) 90 percent (%) improvement in tender or swollen joint counts and \u2265 90% improvement in 3 of the 5 remaining ACR core measures: 1) physician's global assessment of disease activity, 2) subject's global assessment, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire (HAQ), and 5) C-reactive protein (CRP)", 
                "measure": "Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Number of Participants Acheiving European League against Rheumatism (EULAR) Good and/or Moderate Response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Number of Participants Acheiving Low Disease Activity or Remission Based on Clinical Disease Activity Index (CDAI)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Number of Participants Acheiving Low Disease Activity or Remission Based on Simplified Disease Activity Index (SDAI)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Change from Baseline in Clinical Disease Activity Index (CDAI)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Change from Baseline in Simplified Disease Activity Index (SDAI)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "Number of Tender/Painful Joints using the 28 joint count", 
                "measure": "Change from Baseline in Number of Tender/Painful Joints", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "Number of Swollen Joints using the 28 joint count", 
                "measure": "Change from Baseline in Number of Swollen Joints", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "Physician Global Assessment of Disease Activity a 0 to 10 scale, with 0 = no disease activity.", 
                "measure": "Change from Baseline in Physician Global Assessment (PGA) of Disease Activity", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "Subject Global Assessment of Disease Activity as measured on a 0 to 10 scale, with 0 = no disease activity.", 
                "measure": "Change from Baseline in Subject Global Assessment of Disease Activity", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "Subject General Health as measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = very well and 100 mm = extremely bad.", 
                "measure": "Change from Baseline in Subject General Health", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "Subject Pain as measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no pain and 100 mm = most severe pain.", 
                "measure": "Change from Baseline in Subject Pain", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "description": "The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.", 
                "measure": "Change from Baseline in C-Reactive Protein (CRP)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Change from Baseline in Health Assessment Questionnaire Disability and Discomfort Scales (HAQ-DI)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Change from Baseline in Euro Qol EQ-5 Dimensions Questionnaire (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Change from Baseline in Short Form-36 Health Survey (SF-36)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Change from Baseline in Patient Acceptable Symptom State (PASS)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Change from Baseline in Vectra disease activity (DA) levels", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Number of Participants with Positive Etanercept Anti-drug Antibody Status", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }, 
            {
                "measure": "Number of Participants with Positive Etanercept Neutralizing Anti-drug Antibody Status", 
                "safety_issue": "No", 
                "time_frame": "12 weeks, 24 weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}